Community manager

You are here:-Community manager
Community manager

About Community manager

This author has not yet filled in any details.
So far Community manager has created 105 blog entries.

Mining Chemical Libraries for New Antibacterials – Session 2

In this webinar, the recording of Carl Balibar's presentation 'Mining of chemical libraries for new antibacterials' (original webinar on 21 May) will be followed by another live Q&A session with Carl. Speaker: Carl Balibar, Principal Scientist, Merck Research Laboratories Moderator: Benjamin Blasco, Discovery Senior Project Manager, GARDP Despite the promise of target-based drug discovery ushered in by the genomics era, no mechanistically novel rationally designed antibiotic has reached clinically utility to address the threat of multi-drug resistant bacterial pathogens. Phenotypic

Mining Chemical Libraries for New Antibacterials – Session 22019-05-21T08:47:53+00:00

CARB-X 2019 Funding Rounds Webinar

Thursday, May 16, 2019 03:00 PM CEST - 04:00 PM CEST Kevin Outterson, CARB-X Executive Director, and Karen Gallant, CARB-X Global R&D Project Director, present details of CARB-X’s four new funding rounds announced April 30, 2019, and answer questions during this webinar. To attend the live webinar, please register by completing the form on the right. Find more information and a registration link here. A recording of the webinar will be available for viewing shortly after the event.

CARB-X 2019 Funding Rounds Webinar2019-05-14T09:19:31+00:00

Infection models for antimicrobial R&D: Intracellular models

Speaker: Françoise van Bambeke, Research Director Cellular and Molecular Pharmacology, Louvain Drug Research Institute, Catholic University of Louvain (FR) Moderator: Laura Piddock, Director of Scientific Affairs, GARDP In this webinar, Françoise van Bambeke will talk about intracellular activity of antibiotics. Topics discussed will include: The role of intracellular survival in chronic infections and its contribution to poor response to antibiotics In vitro models to study intracellular activity of antibiotics Cellular pharmacokinetic (PK) parameters predictive of intracellular potency for antibiotics

Infection models for antimicrobial R&D: Intracellular models2019-05-06T09:33:17+00:00

New initiatives to support AMR innovation (BSAC Spring Conference 2019)

BSAC Spring Conference 2019:Global views, local problems: Innovative solutions to AMR and infection challenges21 – 22 March 2019, International Convention Centre, Birmingham, UKParallel session one 'New initiatives to support AMR innovation' co-developed by GARDP and CARB-X Public health driven R&D of antibiotics for priority drug resistant infections Dr Seamus O'Brien, R&D Director, Global Antibiotic R&D Partnership (GARDP) CARB-X: Building A Portfolio of New Antibiotics, Vaccines & Diagnostics with Open Science Dr Richard Lawson, Director of the

New initiatives to support AMR innovation (BSAC Spring Conference 2019)2019-05-02T11:35:23+00:00

Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research

Speaker: William J. Weiss, Director, PreClinical Services, University of North Texas System College of Pharmacy Moderator: Peter Warn, Senior Vice President, Anti-infective Discovery, Evotec In this webinar, William J. Weiss will introduce experimental design of animal models for antimicrobial research. He will discuss questions such as Where to start and what model to use? Are animal models of bacterial infection reflective of the clinical condition? Are in vivo animal model results predictive of clinical efficacy? Register here for this

Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research2019-05-06T09:34:40+00:00

Resistance testing – beyond serial passage experiments

Pre-conference workshop: 'Resistance testing – beyond serial passage experiments' 12th Berlin Conference on Life Sciences - Novel Antimicrobials & AMR Diagnostics, 14-15 March 2019, Berlin Emergence of mutational resistance - Threat or myth? Ursula Theuretzbacher, Center for Anti-Infective Agents, Austria Testing of dual/multiple target drugs Michael Mourez, Evotec ID Lyon, France Testing of single target drugs Diarmaid Hughes, Uppsala University & ENABLE, Sweden Jointly organized with:                  

Resistance testing – beyond serial passage experiments2019-04-08T12:19:43+00:00


How to steward new antibiotics into low- and middle-income countries (LMICs)?
– by Marc Mendelson & Adrian Brink

Despite the many health system challenges faced by resource-poor LMICs, access to new antibiotics used in the treatment of multi-drug resistant (MDR) and extensively-drug resistant (XDR) bacterial infections should be a fundamental right, which must be achieved in order to ensure equity in clinical management of bacterial infection for a global community. Historically this has not been achieved, but rather populations in high income countries have benefitted, first and foremost. This basic right will need to be enabled by


How to steward new antibiotics into low- and middle-income countries (LMICs)?
– by Marc Mendelson & Adrian Brink
2019-03-27T10:01:44+00:00

Mining Chemical Libraries for New Antibacterials

Speaker: Carl Balibar, Principal Scientist, Merck Research Laboratories Moderator: Benjamin Blasco, Discovery Senior Project Manager, GARDP Despite the promise of target-based drug discovery ushered in by the genomics era, no mechanistically novel rationally designed antibiotic has reached clinically utility to address the threat of multi-drug resistant bacterial pathogens. Phenotypic screening remains the primary source for new antibacterial compounds, which mainly come from mining various chemical libraries. In this webinar, Carl Balibar (Merck Research Laboratories) will discuss screen design, target bias,

Mining Chemical Libraries for New Antibacterials2019-05-06T09:35:51+00:00


The REPAIR Impact Fund: Reflections from the first year
– by Aleks Engel

Antimicrobial resistance (AMR) is a massive and growing concern worldwide. What can stop it? It is a complex and far-reaching problem with no easy answers, but we are trying to take important first steps. The REPAIR Impact Fund was launched on the 28th of February 2018. With the first year behind us, I reflect on some surprising lessons learned, thoughts about the future, and finally a more personal perspective. As one of the largest dedicated for-profit life science investors,


The REPAIR Impact Fund: Reflections from the first year
– by Aleks Engel
2019-03-01T11:47:01+00:00


Turning the tide on R&D – WHO launches first data call to review pre-clinical pipeline to tackle antibiotic resistance
– by Sarah Paulin and Peter Beyer

The R&D pipeline for new antibacterials to treat increasingly resistant bacterial infections is virtually dry. Very few classes of new antibiotics in particular to treat Gram-negatives have come to the market since the “golden age” of antibiotic discovery. The World Health Organization’s (WHO) global analysis of the clinical pipeline against the priority pathogens in 2017 and 2018 showed that the current pipeline is not very promising to keep up with the evolving resistant bacterial infections with only one of


Turning the tide on R&D – WHO launches first data call to review pre-clinical pipeline to tackle antibiotic resistance
– by Sarah Paulin and Peter Beyer
2019-03-14T14:18:43+00:00


Time to pull out all the stops in the fight against superbugs
– by Kevin Outterson

Great progress on push incentives In the Review on Antimicrobial Resistance (AMR), Lord Jim O’Neill called for a Global AMR Fund with $2 billion over five years. In the past few years, we have seen impressive efforts of new initiatives for research against drug-resistant infections, starting with BARDA, NIAID, Wellcome Trust, JPIAMR, and ND4BB’s ENABLE and TRANSLOCATION projects. In 2016, CARB-X was launched to fund and support innovative early development, GARDP joined the team as a developer, and 2018 saw


Time to pull out all the stops in the fight against superbugs
– by Kevin Outterson
2019-03-01T11:48:35+00:00


Antibacterial drugs: Clinical development for non-developers
Part 3: Non-traditional approaches

Moderator: David Shlaes, Anti-infectives consulting, retired Speakers: Ian Friedland, Clinical consultant, Friedland Strategic Consulting, LLC Sumathi Nambiar, Director, Division of Anti-Infective Products, Office of Antimicrobial Products, CDER, FDA Mair Powell, Senior Clinical Assessor, Health Products Regulatory Authority (Ireland) The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. Our first webinar was devoted to more traditional approaches (Tiers A and B),


Antibacterial drugs: Clinical development for non-developers
Part 3: Non-traditional approaches
2019-04-10T07:20:42+00:00


NIAID Resources to Facilitate Discovery & Development
of Anti-Infectives

Speakers: Ann Eakin, Senior Scientific Officer Office of Biodefense, Research Resources & Translational Research, DMID/NIAID/NIH Dan Pevear, Sr. Vice President, Biology and Grants Development, VenatoRx Pharmaceuticals Incorporated Moderator: François Franceschi, Project leader AMREP, GARDP In this webinar, Ann Eakin (US National Institute of Allergy and Infectious Diseases, NIAID) provided an overview of the various mechanisms of support offered by NIAID to facilitate the discovery and development of drugs, vaccines and diagnostics targeting infectious diseases. The types of support that were


NIAID Resources to Facilitate Discovery & Development
of Anti-Infectives
2019-04-10T07:20:29+00:00


Why we need to prioritize developing antibiotics for children
– by Manica Balasegaram

A question I’m frequently asked is “with the rise of drug-resistant infections, how does GARDP decide where to focus its efforts”? It’s a reasonable question. And our approach is simple. We consider the priority pathogens identified by World Health Organization (WHO), but also consider the needs and gaps for diseases and key populations when defining which antibiotics to develop. In this way, our efforts focus on global public health priorities and indications less likely to be developed by others.


Why we need to prioritize developing antibiotics for children
– by Manica Balasegaram
2019-04-30T13:14:16+00:00

BSAC Antimicrobial Chemotherapy Conference 2019

Antimicrobial Chemotherapy Conference 2019 - An ABC for Everyone Involved in Developing New Antimicrobials 15 January 2019, London Organized by the British Society for Antimicrobial Chemotherapy (BSAC) in collaboration with GARDP Session 1: Antimicrobial drug discovery - an essential overview Opening Remarks Laura Piddock, Head of Scientific Affairs, Global Antibiotic R&D Partnership (GARDP) The risks of clinical development from the perspective of the antibacterial discovery scientist David Shlaes, Former Professor of Medicine, Case Western Reserve University,

BSAC Antimicrobial Chemotherapy Conference 20192019-02-15T09:34:14+00:00

CARB-X: Combating Antibiotic Resistance Globally Webinar

On 15 January 2019, Professor Kevin Outterson, executive director of CARB-X, will be featured in a webinar to introduce and explain the public-private partnership CARB-X, which is dedicated to the early development of innovative antibiotics, vaccines, and other products to fight superbugs. Find more information and a registration link here.

CARB-X: Combating Antibiotic Resistance Globally Webinar2019-01-11T15:19:20+00:00


Recent approvals – do they make a difference?
– by Ursula Theuretzbacher

Six new antibiotics have been approved by the U.S. Food and Drug Administration (FDA) over the last four years. So, at a first glance it seems that there is renewed interest in developing new antibiotics against Gram-negative pathogens. Nevertheless, all six antibiotics – ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, plazomicin, eravacycline, and omadacycline are improved derivatives of well-known antibiotic classes to address class-specific resistance mechanisms. Five of these antibiotics have been developed against infections mainly caused by Gram-negative pathogens, omadacycline, a tetracyline


Recent approvals – do they make a difference?
– by Ursula Theuretzbacher
2019-03-01T11:49:29+00:00

New Strategies in Antibiotic Drug Development

On December 13th, 2018, Collaborative Drug Discovery (CDD) will host a webinar on New Strategies in Antibiotic Drug Development with Dr. Arthur “AJ” Campbell & Dr. Cheryl Quinn. The talk is hosted by CDD, in conjunction with Pew Trusts and moderated by Keystone Symposia CSO Dr. Thale Jarvis with an introduction from Dr. Wes Kim, Senior Officer of Pew Trust's Antibiotic Resistance Project. The discussion will be highly informed with a focus on: How we can move the needle

New Strategies in Antibiotic Drug Development2019-01-11T15:20:58+00:00

Stemming the Superbug Tide: Just a Few Dollars More – Looking at the New OECD Report on AMR

On 11 December, 14:00 GMT, the Leading Health System Network (LHSN), a collaborative network of healthcare leaders and organisations, will host a webinar discussing the OECD report ‘Stemming the Superbug Tide: Just a Few Dollars More’. This report describes the long-term public health and economics consequences of the rise in AMR and identifies effective solutions to tackle this top public health priority. For more information visit the LHSN website.

Stemming the Superbug Tide: Just a Few Dollars More – Looking at the New OECD Report on AMR2019-01-11T15:21:15+00:00


More than one model to stimulate antimicrobial drug development
– by Jim O’Neill

When I first started leading the AMR Review in 2014, I soon came to the conclusion that, if the current model wasn’t delivering new antimicrobial drugs, the solution was obvious: launch a new public purpose-focused entity dedicated to developing and producing new antimicrobials. When I shared this hunch with others, I was advised that it couldn’t be done without the major pharmaceutical companies, as they were the only ones with the expertise to produce and distribute drugs. I let this


More than one model to stimulate antimicrobial drug development
– by Jim O’Neill
2019-03-01T11:50:18+00:00

The AMR Studio – A podcast by the Uppsala Antibiotic Center

The Uppsala Antibiotic Center launches their newest outreach project, "The AMR Studio", with the occasion of the World Antibiotic Awareness Week 2018. The AMR Studio is a podcast dedicated to highlighting the multidisciplinary research on antimicrobial resistance that is happening around the world. Formatted around interviews with professionals working in all aspects of the topic, they aim to bring the global and trans-sectorial nature of the fight against antimicrobial and antibiotic resistance to anyone with an interest. In

The AMR Studio – A podcast by the Uppsala Antibiotic Center2019-01-11T15:21:59+00:00

External blogs in the field

The views and opinions expressed in this blog are solely those of the original author(s) and do not necessarily represent those of GARDP, their donors and partners, or other collaborators and contributors. GARDP is not responsible for the content of external sites. John H. Rex: Solutions for Antimicrobial Resistance David Shlaes: Antibiotics - The Perfect Storm Longitude Prize - Blog The Center For Disease Dynamics, Economics & Policy (CDDEP)

External blogs in the field2019-03-01T11:51:02+00:00

Making Safety a Part of Drug Design

Speaker: Claire Sadler, Senior Toxicologist, ApconiX, UKModerator: Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria* This presentation was also part of the GARDP and CARB-X co-organized session 'Antibiotic Bootcamps for Developers: Preclinical Toxicology' at the ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance *In this webinar, Claire Sadler discussed the toxicological challenges and pitfalls of antibiotic discovery programs. Potential safety risks are the major reason for terminating a program in early phases of antibiotic drug development. This webinar

Making Safety a Part of Drug Design2018-11-14T15:38:08+00:00

Bootcamp: Preclinical Toxicology (ESCMID/ASM 2018)

Antibiotic Bootcamps for Developers: Preclinical Toxicology ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 4-7 September 2018, Lisbon A collaborative project of GARDP and CARB-X Chair person: Ursula Theuretzbacher Speakers: Terry Miller, Claire Sadler, Ryan Cirz Roundtable discussion: Terry Miller, Claire Sadler, Ryan Cirz, Ursula Theuretzbacher Introduction Pitfalls in Preclinical Development from the Regulatory Perspective (FDA) (Terry Miller) Making Safety a Part of Drug Design (Claire Sadler) Real life story of unexpected toxicity - Lessons to

Bootcamp: Preclinical Toxicology (ESCMID/ASM 2018)2019-01-07T09:18:26+00:00

FDA’s Plan to Combat Antibiotic Resistance

On Friday, Sept. 14, 2018, at 10 a.m. EDT, The Pew Charitable Trusts hosts Dr. Scott Gottlieb, commissioner of the U.S. Food and Drug Administration, as he announces the agency’s plans to combat antibiotic resistance. Following Gottlieb’s remarks, a panel of FDA senior officials will further explore the agency’s new and ongoing activities to support antibiotic innovation and ensure that antimicrobial drugs are used according to good stewardship practices in human medicine and animal agriculture. Click here to

FDA’s Plan to Combat Antibiotic Resistance2019-01-11T15:22:18+00:00

A Discussion with Chris Lipinski and Barry Bunin

On September 13th, 2018, Collaborative Drug Discovery (CDD) will host a webinar with Christopher Lipinski and Barry Bunin. The discussed topics will include: Going beyond the Rules of 5 New technologies to better assess the quality of screening data Experimental culture and sociology as a factor in clustering of results Plus topics you would not expect, like how scientists can (and should) respond to the growing opioid addiction crisis – which has actually lowered life expectancy in America

A Discussion with Chris Lipinski and Barry Bunin2019-01-11T15:22:38+00:00

Bootcamp: Medicinal Chemistry (ESCMID/ASM 2018)

Antibiotic Bootcamps for Developers: Medicinal Chemistry ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 4-7 September 2018, Lisbon A collaborative project of GARDP and CARB-X Chair persons: John Griffin and Heinz Moser Speakers: Andrea Decker, Heinz Moser, John Griffin Roundtable discussion: Andrea Decker, Heinz Moser, John Griffin, John H. Rex Introduction Drug-Likeness: Physicochemical Properties in Small-Molecule Drug Discovery (Andrea Decker) Drug Discovery of Antibiotics: The Importance of Physicochemical Properties (Heinz Moser) Emerging Artificial Intelligence Approaches in

Bootcamp: Medicinal Chemistry (ESCMID/ASM 2018)2019-01-07T09:19:00+00:00


Antibacterial drugs: Clinical development for non-developers
Part 2: Development of antibacterial drugs targeting specific pathogens

Moderator: David Shlaes, Anti-infectives consulting, retired Speakers: Ian Friedland, Clinical consultant, Friedland Strategic Consulting, LLC Sumathi Nambiar, Director, Division of Anti-Infective Products, Office of Antimicrobial Products, CDER, FDA Mair Powell, Senior Clinical Assessor, Licensing Division, Medicines and Healthcare products Regulatory Agency (UK) The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. Our first webinar was devoted to more traditional approaches


Antibacterial drugs: Clinical development for non-developers
Part 2: Development of antibacterial drugs targeting specific pathogens
2018-10-01T09:41:35+00:00

Battle of the Bugs: Designing the Best Approach in the Fight Against Infectious Disease

Webinar on models for drug development programmes by Charles River: The emergence of antibiotic-resistant bacteria and genetic variance amongst viruses has embattled the development of effective treatment and vaccination against infectious diseases, leading to a worldwide crisis in medical care. This webinar will help you choose the correct models for your drug development program; from early in vitro screening assays providing identification of efficacy, to a range of clinically relevant in vivo models. We also explore the use

Battle of the Bugs: Designing the Best Approach in the Fight Against Infectious Disease2019-01-11T15:25:40+00:00

PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?

Speaker: William Hope, Centre of Antimicrobial Pharmacodynamics, University of Liverpool Moderator: Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria * This presentation was also part of the GARDP and CARB-X co-organized session 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th ECCMID in Madrid in April 2018. * In this webinar, William Hope talked about the role of pharmacokinetics and pharmacodynamics for antimicrobial drug development. He discussed the EMA guideline on the use

PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?2018-10-01T09:39:04+00:00


Antibacterial drugs: Clinical development for non-developers
Part 1: Traditional development – tiers A and B

NEW: Download a summary of this webinar here! Speaker: David Shlaes - Anti-infectives consulting, retired Moderator: Laura Piddock - Head of Scientific Affairs, GARDP In this presentation we introduce the relationship between the discovery phase and later clinical development. We discuss in some depth traditional clinical development pathways (tiers A and B) focusing on the non-inferiority trial design. We hosted a live webinar with David Shlaes and Laura Piddock on June 13, 2018. If you have questions or comments,


Antibacterial drugs: Clinical development for non-developers
Part 1: Traditional development – tiers A and B
2018-10-01T09:42:40+00:00

Drug Discovery Data Insights: Highly Accessible SAR Data is Transforming the Drug Discovery Informatics Landscape

On June 26th, 2018, Collaborative Drug Discovery (CDD) hosted a webinar where moderator Ashley Farley, Associate Officer of Knowledge & Research Services at the Bill & Melinda Gates Foundation (BMGF) discussed drug discovery data with Dr. Andrew Leach from ChEMBL and Dr. Evan Bolton from PubChem. The presenters discussed the emergence of freely available PubChem and ChEMBL resources for chemical and biological Structure-Activity-Relationship (SAR) data and their impact on the global drug discovery informatics landscape. The relationship between

Drug Discovery Data Insights: Highly Accessible SAR Data is Transforming the Drug Discovery Informatics Landscape2019-01-11T15:25:30+00:00

Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent?

John H. Rex Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed

Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent?2019-01-07T09:20:25+00:00

PK-PD in support of accelerated programmes: how much is enough?

William Hope Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed up

PK-PD in support of accelerated programmes: how much is enough?2019-01-07T09:20:41+00:00

US regulatory tools for expedited antibacterial development programmes

Sumathi Nambiar Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed up

US regulatory tools for expedited antibacterial development programmes2019-01-07T09:20:56+00:00

EU regulatory tools for expedited antibacterial development programmes

Marco Cavaleri Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed up

EU regulatory tools for expedited antibacterial development programmes2019-01-07T09:21:14+00:00

Decisions, Decisions: What Makes a Good Hit? A Good Lead? Why Do You Write a TPP? How Do You Write a TPP?

Antibiotic Bootcamps for Developers A collaborative project of CARB-Xed, GARDP, ASM, and ESCMID 5-8 September 2017, ASM-ESCMID Conference, Boston Moderator: Lynn Silver, LL Silver Consulting, LLC Discussants:  Lynn Silver, LL Silver Consulting, LLC Tom Dougherty, Harvard Medical School John Tomayko, Infectious Diseases Consultant Sherman T. Waddell, Prokaryotics, Inc. Date : September 5th, 2017

Decisions, Decisions: What Makes a Good Hit? A Good Lead? Why Do You Write a TPP? How Do You Write a TPP?2019-01-07T09:21:28+00:00

How Does a Molecule Become a Physical Medicine to be Given to a Human: The Importance of Chemistry, Manufacturing, and Controls

Antibiotic Bootcamps for Developers A collaborative project of CARB-Xed, GARDP, ASM, and ESCMID 5-8 September 2017, ASM-ESCMID Conference, Boston Moderator: Tim Keutzer, Spero Therapeutics Discussants: Tim Keutzer, Spero Therapeutics Evan Hecker, Spero Therapeutics Mike Young, Tedor Pharma Inc Andrew Barlow, Syner-G Pharma Consulting Date : September 5th, 2017

How Does a Molecule Become a Physical Medicine to be Given to a Human: The Importance of Chemistry, Manufacturing, and Controls2019-01-07T09:21:42+00:00

Clinical Microbiology for a Development Program

Antibiotic Bootcamps for Developers A collaborative project of CARB-Xed, GARDP, ASM, and ESCMID 5-8 September 2017, ASM-ESCMID Conference, Boston Moderator: Judith Steenbergen, Paratek Pharmaceuticals Discussants: Erika Matuschek, EUCAST: Investigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing Kevin Krause, Achaogen: NDA Requirements: Surveillance, Clinical Trial Data, Breakpoints Robin Patel, Mayo Clinic: Making Antibacterial Susceptibility Available in Clinical Practice Roundtable: Pitfalls in Development Date : September 5th, 2017

Clinical Microbiology for a Development Program2019-01-07T09:21:54+00:00

Antoine Andremont

Antoine Andremont is currently Emeritus Professor at the Paris Diderot University Medical School, France, a scientific advisor at the French Ministry of Higher Education, Research and Innovation, and serves as an expert witness for the French National Highest Judiciary Court (Cour de Cassation). He is also the co-founder and a senior scientific advisor at biotechnology company Da Volterra - which he created in 2000 to research and understand the impact of antibiotics on the intestinal flora microbiota, the development and

Antoine Andremont2018-08-29T11:29:12+00:00

John N van den Anker

John N van den Anker is a renowned paediatric consultant based at the Children’s National Medical Center Washington, DC, whose research has resulted in a much more evidence-based use of antibacterial agents such as aminoglycosides, cephalosporins, penicillins, meropenem, and vancomycin in children. John holds many titles including, the Evan and Cindy Jones Endowed Professor of Paediatric Clinical Pharmacology at Children’s National Medical Center; the Eckenstein-Geigy Distinguished Professor in Paediatric Pharmacology and Pharmacometrics at the University of Basel Children’s Hospital in

John N van den Anker2018-10-03T14:06:45+00:00

Jesús Rodríguez-Baño

Jesús Rodríguez-Baño is Professor of Medicine at the University of Seville and Head of the Infectious Diseases division at Hospital Universitario Virgen Macarena in Seville, Spain. He is also Scientific Chair of the Spanish Network for Research in Infectious Diseases (REIPI), which is funded by Instituto de Salud Carlos III, and President-Elect of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Jesús is a medical doctor and specialist in internal medicine, who gained his PhD in medicine in

Jesús Rodríguez-Baño2018-03-13T08:16:28+00:00

Michael Barbachyn

Michael Barbachyn is the Brummel Chair and Professor of Organic Chemistry at Calvin College, Michigan, US, and an independent consultant at Barbachyn Consulting. Michael has over 27 years’ experience in medicinal chemistry as a research scientist following periods at Upjohn, Pharmacia & Upjohn, Bristol-Myers Squibb, Pharmacia, Pfizer and AstraZeneca, focused on anti-infectives. Michael also has 12 years’ pharmaceutical industry management experience as an associate director and director in antibacterial medicinal chemistry at Pharmacia and then Pfizer; and as a director

Michael Barbachyn2018-03-26T07:54:34+00:00

Greg Basarab

Greg Basarab is Principal Research Officer and Associate Director at the University of Cape Town (UCT), Drug Discovery and Development Centre (H3D). He is Head of drug metabolism and pharmacokinetics (DMPK) and pharmacology groups located at Groote Schuur Hospital, Head of Institute of Infectious Diseases and Molecular Medicine, and Head of Medicinal Chemistry groups within the UCT Chemistry Department. He lectures at the UCT Medical School on Drug Disposition and Pharmacology. Greg worked in various aspects of antibacterial and antifungal

Greg Basarab2018-03-12T13:20:21+00:00

Alex van Belkum

Alex van Belkum is currently Scientific Director of Microbiology Research at bioMérieux, a diagnostics company based in the South of France. He is also a fellow of the American Academy of Microbiology. Alex is a microbiologist in the data analytics unit of bioMérieux with a prime interest in next generation sequencing, and the use of other data-rich technologies in clinical microbiology. His long career has been dedicated to the research of molecular epidemiology, molecular and culture-based diagnostics and antimicrobial resistance

Alex van Belkum2018-08-29T13:54:05+00:00

Julia Bielicki

Julia Bielicki is currently a consultant in Paediatric Infectious Diseases and Infection Prevention and Control at the University of Basel Children’s Hospital. She is also an active researcher with the Paediatric Pharmacology Division at the University of Basel Children’s Hospital and a Senior Lecturer with the Paediatric Infectious Diseases Research Group at St George’s University of London. Furthermore, Julia is involved in developing a national antimicrobial stewardship programme in Switzerland. Julia’s research focuses on observational and interventional studies that aim

Julia Bielicki2018-10-09T12:12:44+00:00

Helen W Boucher

Helen Boucher is currently Director of the Infectious Diseases Fellowship Program, Director of the Heart Transplant and Ventricular Assist Device Infectious Diseases Program, and staff physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center. She is also Professor of Medicine at Tufts University School of Medicine in Boston, Massachusetts. Helen trained as a medical doctor at the University of Texas Medical School, Houston, before completing her internship, residency and chief residency in Internal Medicine at

Helen W Boucher2018-03-09T12:32:06+00:00

Pamela Brown

Pamela Brown has over 30 years’ experience in anti-infective drug discovery gained within the biotech and pharmaceutical sectors. She is currently a consultant in Antibacterial Drug Discovery and Medicinal Chemistry offering independent advice and expertise to small and medium-sized enterprises (SMEs), biotechs and academic institutions. Pam was Director, Medicinal Chemistry at Cantab Anti-infectives for five years following its inception in 2012. There, Pam led the medicinal chemistry team towards novel polymyxins, resulting in a commercial deal with Spero Therapeutics in

Pamela Brown2018-03-08T14:01:34+00:00

Karen Bush

Karen Bush is a PhD graduate in biochemistry from Indiana University (IU). She spent 36 years in pharmaceutical research before joining the IU faculty to continue her focus on antibiotic drug discovery and development, based on her research on antibiotic resistance mechanisms. Karen’s major research has been in the area of beta-lactamases, the enzymes primarily responsible for antibiotic resistance to penicillins and cephalosporins and she has been a leader in beta-lactamase characterization and nomenclature. Karen’s research group has studied the

Karen Bush2018-03-09T14:47:21+00:00

Vincent Cattoir

Vincent Cattoir is currently Professor of Clinical Microbiology at the University of Rennes 1, as well as a clinical microbiologist at the Bacteriology department of the University Hospital of Rennes, France. Vincent is the Director of the Lab Enterococci, affiliated to the National Reference Center for Antimicrobial Resistance. He is also a senior scientist in the INSERM U1230 Pharmaceutical Biochemistry at the University of Rennes 1, currently focused on regulator RNAs (sRNAs) involved in the pathogenicity and antimicrobial resistance in

Vincent Cattoir2018-08-30T07:54:24+00:00

Ryan Cirz

Ryan Cirz is Vice President of Infectious Disease Research and Head of the Postdoctoral Program at Achaogen, which focuses on discovering, developing and commercializing innovative antibacterials to treat multi-drug resistant (MDR) Gram-negative infections. Ryan has worked on antibacterial discovery and development at Achaogen for 11 years in roles of increasing seniority, focused almost exclusively on new agents for MDR Gram-negative pathogens. He currently oversees the progress of Achaogen’s early-stage (pre-investigational new drug) pipeline and provides intellectual insight/support to all things

Ryan Cirz2018-03-26T07:58:45+00:00

Anthony Coates

Anthony Coates is the Founder and Chief Scientific Officer of Helperby Therapeutics, a biopharmaceutical company dedicated to developing the next generation of lifesaving antibiotics. Anthony created the company in 2002 and together with colleague Yanmin Hu invented Antibiotic Resistance Breakers (ARBs), a new form of ‘antibiotic renewable’ technology. With existing antibiotic treatments rapidly becoming obsolete, Helperby’s unique antibiotic technology outsmarts highly resistant bacteria by combining ARBs with old antibiotics such as colistin, to create a new and sustainable commercially viable

Anthony Coates2018-10-03T12:00:24+00:00

Matthew Cooper

Matthew Cooper is co-founder, Director and Chief Executive Officer of Inflazome, which develops inflammasome inhibitors for chronic inflammatory diseases. Matt is also Co-Founder and Director of Defensin Therapeutics and Affiliate Professor at Trinity College Dublin. He holds a fractional Professorial Research Fellow appointment at the University of Queensland, where he is Professor of Chemical Biology at the Institute of Molecular Bioscience and, Affiliate Professor in the School of Chemistry and Molecular Biology. Matt obtained his PhD in 1995 in organic

Matthew Cooper2018-07-03T07:52:51+00:00

Patrice Courvalin

Professor Patrice Courvalin is an internationally recognized expert in the genetics and biochemistry of antibiotic resistance, and in the transfer and heterologous expression of genetic information. He first described and then elucidated, vancomycin resistance in Enterococcus. Patrice’s research has led to a revision of the dogma describing natural dissemination of antibiotic-resistance genes. He and his colleagues demonstrated that a wide variety of pathogenic bacteria can promiscuously exchange genetic material, and proved that conjugation could account for dissemination of genes between

Patrice Courvalin2018-03-12T13:24:47+00:00

Mike Dawson

Mike Dawson is a consultant in antimicrobial research, who has spent the last 14 years working in the biotech sector. Mike also has over 20 years’ experience in the pharmaceutical industry gained at GSK. As Head of Biotransformation and Natural Product Chemistry he played leading roles in natural product based drug discovery and the application of biological processes to drug manufacturing. He left GSK in 2003 to set up Novacta Biosystems where, as Chief Scientific Officer (CEO), he led the

Mike Dawson2018-03-08T14:14:35+00:00

George L Drusano

George Drusano is director of the Institute for Therapeutic Innovation at the University of Florida, whose mission is to improve the therapy for serious infectious diseases. After graduating magna cum laude from the honours programme at Boston College, George graduated cum laude from the University of Maryland School of Medicine in Baltimore. He completed his medical internship and residency at the University of Maryland Hospital, where he was also Chief Medical Resident and a Fellow in Medicines in Infectious Diseases.

George L Drusano2018-03-08T14:30:28+00:00

Jacques Dumas

Jacques Dumas is a trained chemist with over 20 years’ experience in discovery to clinical proof-of-concept in infectious diseases and oncology. He has been Chief Scientific Officer (CSO) of Tetraphase Pharmaceuticals since July 2015, where he oversees non-clinical sciences and CMC (Chemistry, Manufacturing and Controls) activities to support the company’s product pipeline. Jacques became CSO at Idenix Pharmaceuticals in January 2014, then Vice President at Merck following Merck’s acquisition of Idenix. Between 2007 and 2014, Jacques held several positions at

Jacques Dumas2018-03-12T07:45:59+00:00

Barry I Eisenstein

Barry Eisenstein is the chair of the Scientific and Business Advisory Board of CARB-X, a public-private partnership based at Boston University, devoted to new antimicrobial drug and diagnostic development. Barry received his medical degree from Columbia University and subsequently trained in internal medicine and infectious diseases at the University of North Carolina. He has spent his career in academy and industry, serving as Chief of the Infectious Diseases division at the University of Texas Health Science Center, San Antonio then

Barry I Eisenstein2018-03-09T07:08:05+00:00

Alice Erwin

Alice Erwin is an independent scientific consultant, providing advice on antibiotic discovery to academic and industrial research groups. She also conducts due-diligence evaluation of antibacterial programmes being evaluated as in-licensing or investing opportunities. Alice is an infectious disease microbiologist with experience in both academic and industrial settings. Her scientific research over the past thirty years has revolved around the structure and function of bacterial membranes, with particular interest in the contribution of lipopolysaccharides to both the pathogenesis and the intrinsic

Alice Erwin2018-08-29T12:18:21+00:00